Biotech success, 2002 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech success, 2002

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who started this subject	3/13/2002 7:04:52 PM
From: Miljenko Zuanic	of 117

Wednesday March 13, 1:41 pm Eastern Time Press Release SOURCE: Cell Therapeutics (UK) Limited; Cell Therapeutics, Inc. TRISENOX(R) Granted Marketing Authorization in Europe from the European Commission LONDON, March 13 /PRNewswire-FirstCall/ -- Cell Therapeutics (UK) Limited, a wholly owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC - news), announced that the European Commission has granted the Marketing Authorization for TRISENOX (arsenic trioxide), indicated for the induction of remission and consolidation in adult patients with relapsed/refractory acute promyelocytic leukemia (APL) characterized by the presence of the t(15:17) translocation and/or the presence of the Pro-Myelocytic Leukemia/Retinioic-Acid-Receptor- alpha (PML/RAR-alpha) gene. Previous treatment should have included a retinoid and chemotherapy. U.S. Food and Drug Administration (FDA) also approved TRISENOX for the treatment of relapsed/refractory APL in September 2000 for marketing in the United States.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next